Hypertrophic Cardiomyopathy Market Set for Transformation

Hypertrophic cardiomyopathy is a condition characterized by abnormal thickening of the heart muscle's left ventricular wall. In healthy individuals, this wall has a certain thickness; however, thickening of the wall beyond normal limits can lead to the development of heart disease. 

Although the disease rarely occurs due to environmental factors or other heart conditions, it is most often considered a hereditary heart disorder passed down through genetic inheritance. This thickening in the heart muscle directly affects the heart's functioning pattern. As a result, disruptions occur in blood circulation, and problems such as arrhythmia (irregular heart rhythm) may be observed. The Delveinsight report evaluates the current situation in this field and the process ahead.

What Are the Symptoms of Hypertrophic Cardiomyopathy?
Hypertrophic cardiomyopathy fundamentally means thickening of the heart muscle. This thickening manifests itself through various symptoms. The main symptoms are as follows:

Shortness of breath
This is one of the first symptoms that emerges due to the thickening of the heart muscle. Thickening of the ventricular wall impairs contraction and relaxation functions. The heart's inability to contract and relax effectively enough makes breathing difficult. Breath control is particularly disrupted during physical exertion; this condition can become evident even while climbing stairs.

Chest pain
This is one of the most commonly encountered symptoms. When the heart muscle thickens, the body's oxygen demand increases. When sufficient oxygen cannot be provided, chest pain begins. As oxygen insufficiency increases, the pain also intensifies.

Palpitations
This is a symptom that is often overlooked. There are many factors in daily life that can cause palpitations (caffeine consumption, psychological stress, etc.). For this reason, a person may not take the problem seriously. However, it is important to take heart palpitations into consideration; they can progress over time and turn into rhythm disorders.

Fainting and exercise intolerance
Thickening causes oxygen insufficiency and shortness of breath. In this condition, the heart and body tire quickly, and exercise capacity decreases. When excessive exertion is expended, warning symptoms such as fainting may occur.

The hypertrophic cardiomyopathy market is expected to show significant growth, driven by increasing disease awareness, improving diagnosis rates, and the emergence of targeted disease-modifying therapies such as Sotagliflozin (ZYNQUISTA) (Lexicon Pharmaceuticals), Ninerafaxstat (Imbria Pharmaceuticals), EDG-7500 (Edgewise Therapeutics), and others.

The recently published Hypertrophic Cardiomyopathy Market Insights report offers a comprehensive understanding of current treatment practices, drugs being developed for hypertrophic cardiomyopathy, the market share of individual treatments, and the current and forecasted market size from 2022 to 2036; this information is segmented according to leading markets [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Hypertrophic Cardiomyopathy Market Summary
- The hypertrophic cardiomyopathy market size was found to be USD 3.2 billion in 7MM in 2025.

- The United States has the largest hypertrophic cardiomyopathy treatment market size in 7MM in 2025, compared to other major markets such as the EU4 countries (Germany, France, Italy, and Spain), the United Kingdom, and Japan.

- The total prevalent HCM cases in 7MM were approximately 11 million in 2025.

- Leading hypertrophic cardiomyopathy companies such as Lexicon Pharmaceuticals, Imbria Pharmaceuticals, Edgewise Therapeutics, Tenaya Therapeutics, Cytokinetics, and others are developing new therapeutic drugs that could become available in the hypertrophic cardiomyopathy market in the coming years.

- Promising hypertrophic cardiomyopathy treatments in clinical trials include Sotagliflozin (ZYNQUISTA), Ninerafaxstat, EDG-7500, TN-201, Aficamten, and others.

Key Factors Driving the Growth of the Hypertrophic Cardiomyopathy Market
- Increasing Prevalence of Hypertrophic Cardiomyopathy: Growing recognition of HCM as one of the most common inherited cardiac disorders is contributing to increased demand for effective treatment options.

- Growing Adoption of Disease-Specific Targeted Therapies: The approval and commercialization of cardiac myosin inhibitors such as mavacamten and aficamten has transformed the HCM treatment landscape by addressing the underlying disease mechanism rather than merely managing symptoms.

- Advances in Genetic Testing and Precision Medicine: The increasing use of genetic screening and molecular diagnosis is enabling better identification of patients with pathogenic variants associated with HCM.

- Expansion of Clinical Trials and Pipeline Developments: The dynamics of the hypertrophic cardiomyopathy market are expected to change over the next decade due to the launch of emerging therapies such as Sotagliflozin (ZYNQUISTA) (Lexicon Pharmaceuticals), Ninerafaxstat (Imbria Pharmaceuticals), EDG-7500 (Edgewise Therapeutics), TN-201 (Tenaya Therapeutics), Aficamten (Cytokinetics), and others.

Sadaf Javed, DelveInsight's Forecasting and Analytics Functional Head, stated that among the emerging therapies, sotagliflozin (ZYNQUISTA) is expected to achieve moderate adoption particularly in patients with HCM and cardiometabolic comorbidities or heart failure-related symptoms, reflecting growing interest in SGLT-mediated cardiovascular therapies. Ninerafaxstat is also expected to see moderate adoption due to its metabolism-focused approach aimed at improving myocardial energy and exercise capacity.

Hypertrophic Cardiomyopathy Market Analysis
- The current treatment landscape for hypertrophic cardiomyopathy remains relatively limited, with a limited number of disease-specific targeted therapies approved to date; these are primarily mavacamten (CAMZYOS) and aficamten (MYQORZO).

- Mavacamten marked the first approval of a disease-modifying cardiac myosin inhibitor for the treatment of symptomatic obstructive HCM and represented a significant advance in targeted HCM management.

- Aficamten emerged as the second cardiac myosin inhibitor approved for obstructive HCM and is regarded as the most notable competitive challenger to mavacamten. Its approval was supported by the positive results of the Phase III SEQUOIA-HCM trial.

- Although current treatments do not provide a cure for HCM, they play an important role in alleviating symptoms, enhancing cardiac performance, and reducing the risk of disease progression.

- Newer targeted approaches focus on addressing excessive cardiac muscle contraction and have the potential to alter disease biology and slow or reverse the structural and functional abnormalities associated with HCM.

- Historically, the pharmacological management of HCM has focused on symptom relief and prevention of complications. In symptomatic patients with preserved ejection fraction, beta-blockers, non-dihydropyridine calcium channel blockers such as verapamil and diltiazem, and disopyramide have remained the mainstay first-line treatment options.

- The HCM development pipeline continues to demonstrate strong momentum and commercial potential, with increasing investments by pharmaceutical and biotechnology companies in targeted cardiac and metabolic therapies.

- Key players, including Lexicon Pharmaceuticals (sotagliflozin), Imbria Pharmaceuticals (ninerafaxstat), Edgewise Therapeutics (EDG-7500), Tenaya Therapeutics (TN-201), and other emerging innovators, are actively advancing new therapeutic approaches and expanding the future treatment landscape for HCM.

Sources 

https://www.memorial.com.tr/hastaliklar/hipertrofik-kardiyomiyopati-nedir

https://www.prnewswire.com/news-releases/hypertrophic-cardiomyopathy-market-set-for-transformation-over-the-next-decade-with-the-emergence-of-targeted-cardiac-therapies-beyond-conventional-beta-blockers-calcium-channel-blockers-and-antiarrhythmic-agents--delveinsight-302852567.html